Find a Clinical Trial

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)

A Phase 3 Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (*HDFN)

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at

ACNS1123:  Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors. 

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-IR Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multi-agent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing

INDUCTION IN NULLIPAROUS WOMEN AT 39 WEEKS TO PREVENT ADVERSE OUTCOMES: A RANDOMIZED CONTROLLED TRIAL

A031201: Phase III Trial of Enzalutamide (NSC#766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Lymphocytic Leukemia/ E1912: A Randomized Phase III Study of PCI-32765-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) (PRO00002012 –

Cardiology/ Medtronic AdaptResponse Study (1_PRO00002070)

Metastatic Non-Small Cell Lung Cancer/ A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving

Optisure Lead Post Approval Study (2_PRO00002407)

Chronic Hepatitis C/ A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis

MULTIPLE SCLEROSIS/ A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION OF TECFIDERA™ (DIMETHYL FUMARATE) WHEN USED IN ROUTINE MEDICAL PRACTICE IN THE

A phase II, Multicenter, Four-Cohort Study of Oral c-MET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (WT), Advanced Non-small Cell Lung Cancer (NSCLC) who have Received One or Two

Treatment Naïve HIV-1 infected subjects/ A Phase 3 Multicenter, Double-blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK 1439) 100 mg Once Daily Versus

Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

Prospective Observational Study of Respiratory Support Provided to Premature Infants at Risk for Respiratory Distress Syndrome

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a

The Project Every Child Protocol: A Registry, Eligibility, Screening, Biology and Outcome Study

Quorum Novartis Signature study, CBGJ398XUS04: Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 6 – BGJ398 for patients with tumors with FGFR genetic

ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND#118613)

The Effects of Harp Music on Anxiety, Depression, and Nausea in Cancer Patients Receiving Chemotherapy

Leukemia (ECOG E3903): Ancillary laboratory protocol for the collection of diagnostic material on patients considered for ECOG treatment trials for leukemia or related hematologic disorders (2_PRO00000429)

HIV (A4001067/1322): An international, multicenter, prospective observational study of the safety of Maraviroc used with optimized background therapy in treatment-experienced HIV-1 infected patients (1_PRO00000036)